Why Is Xenon Pharmaceuticals $XENE Stock Down -28.96% Today? (Find out why any stock moved today on Tickeron.) • Shares of $XENE plunged roughly 28.96% to about $40.74, down from a prior close of $57.35. • The selloff followed a voluntary pause in new patient enrollment for its major depressive disorder (MDD) and bipolar depression studies. • The pause was triggered by neuropsychiatric adverse events tied to its lead candidate, azetukalner, that had not been seen in earlier Phase 2 data. • The company simultaneously submitted a new drug application (NDA) to the FDA for azetukalner in focal onset seizures, but the psychiatry setback overshadowed the milestone. • Analysts were split, with some defending the stock while others cut ratings and price targets. Traders are now watching for dosing-modification updates and the path forward for the epilepsy franchise. $NUVL $PHVS $PVLA $EVMN $APGE $PTGX $IMVT
published
Why Is Xenon Pharmaceuticals $XENE Stock Down -28.96% Today? (Find out why any stock moved today on Tickeron.) • Shares of $XENE plunged roughly 28.96% to about $40.74, down from a prior close of $57.35. • The selloff followed a voluntary pause in new patient
$XENE$NUVL$PHVS$PVLA$EVMN$APGE$PTGX$IMVT
Latest documented BWB result
$META market result
I sold the $META $655 Puts 9/25 for $7.60
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.
